Osteoclasts are the cells responsible for bone resorption, and their number
and rate of formation are critical in determining bone mass, To identify a
nd quantify osteoclasts, as well as to study their formation in bone and in
osteoclastogenic cultures, osteoclast-specific cell markers are required.
Only the calcitonin receptor (CTR) expression unambiguously identifies oste
oclasts and distinguishes them from macrophage polykaryons, However, presen
t autoradiographic methods for CTR detection are cumbersome and time consum
ing. We have developed rabbit polyclonal antibodies specific for the C-term
inal intracellular domain of the mouse and rat C1a CTR. These antibodies la
beled HEK-293 cells stably transfected with CTR (but not untransfected HEK-
293 cells), This labeling is abrogated by preabsorbing the antibodies with
the recombinant antigen, The antibodies immunostained primary mouse and rat
osteoclasts as well as osteoclasts in sections of mouse bone. Osteoclasts
(both mononuclear and multinucleated) formed from mouse bone marrow or sple
en cells cocultured with osteoblasts in the presence of 1,25 dihydroxyvitam
in D-3 and prostaglandin E-2 a ere also specifically immunostained by the C
TR antibodies. Cocultures incubated under conditions that did not allow ost
eoclastogenesis (i.e., omission of mediators or osteoblasts, or culture for
less than 4 days) were not immunostained by CTR antibodies. Autoradiograph
ic detection of I-125-labeled salmon calcitonin combined with CTR immunohis
tochemistry showed that both methods labeled the same cells, A CTR polyclon
al antibody and monoclonal antibody F4/80 were used in combination to show
immunofluorescence labeling of murine osteoclasts and macrophage population
s, respectively, in marrow/osteoblast cocultures. These results indicate th
at simple and rapid CTR antibody-based methods can be used to identify oste
oclasts, and can be used to characterize the antigenic profile of osteoclas
ts by using double immunofluorescence analysis. (C) 1999 by Elsevier Scienc
e Inc. All rights reserved.